enVVeno Medical (NASDAQ:NVNO), Inc. is a clinical-stage medical device company focused on developing minimally invasive treatments for peripheral venous diseases. The company’s core mission is to introduce novel technologies that address the underlying causes of incompetent veins, including varicose veins, with the goal of improving patient outcomes and reducing treatment times. enVVeno’s platform technology is designed to deliver precision therapies through a catheter-based approach, enabling targeted treatment of diseased vessels without the need for extensive surgical intervention.
The company’s lead product candidate, the VenoSeal™ System, is a proprietary polymer-based endovenous occlusion platform intended to seal and close refluxing veins. Unlike thermal ablation or sclerotherapy, the VenoSeal System employs a biocompatible adhesive delivered through a catheter to approximate vein walls, offering a potentially faster recovery and reduced risk of nerve injury. VenoSeal is currently in pivotal clinical trials in the United States and Europe, with the company working to secure regulatory approvals and establish reimbursement pathways ahead of anticipated commercial launch.
Founded in California, enVVeno operates its research, development and manufacturing activities out of Santa Clarita, with additional clinical and regulatory teams located in strategic regions across North America and Europe. The company maintains partnerships with leading vascular clinics and academic medical centers to advance its clinical programs and gather real-world evidence. Through these collaborations, enVVeno aims to build a robust body of clinical data supporting both safety and efficacy of its technology.
enVVeno’s leadership team is led by Chief Executive Officer Todd C. Patterson, a medical device industry veteran with over 25 years of experience in product development and commercialization. The executive management team combines expertise in interventional cardiology, vascular surgery and regulatory affairs, supported by a board of directors and scientific advisory panel comprising renowned specialists in vascular medicine. Together, they guide enVVeno’s strategic roadmap as the company moves toward late-stage development and market entry.
